Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.60 |
| ▸ | XDH | P47989 | 3/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23743756 | 0.96 | ALDH1A1 (0.73) | ALDH1A1SYNJ2APPSOSTXDH | |
| SCHEMBL30350498 | 0.90 | SYNJ2 (0.74) | ALDH1A1SYNJ2APPSOSTXDH | |
| SCHEMBL21588168 | 0.90 | SYNJ2 (0.74) | ALDH1A1SYNJ2APPSOSTXDH | |
| SCHEMBL23743745 | 0.89 | XDH (0.65) | ALDH1A1SYNJ2APPSOSTXDH | |
| SCHEMBL26481156 | 0.88 | SYNJ2 (0.60) | ALDH1A1SYNJ2APPSOSTXDH | |
| SCHEMBL16942322 | 0.86 | ALDH1A1 (0.76) | ALDH1A1XDHABCB1 | |
| SCHEMBL10335311 | 0.85 | XDH (0.67) | ALDH1A1SYNJ2APPSOSTXDH | |
| SCHEMBL28545861 | 0.85 | ALDH1A1 (0.78) | ALDH1A1XDHABCB1 | |
| SCHEMBL17179811 | 0.83 | ALDH1A1 (1.00) | ALDH1A1XDHABCB1 | |
| SCHEMBL28213500 | 0.81 | ALDH1A1 (0.71) | ALDH1A1SOSTXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| WO-2019233440-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES | 江苏新元素医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | SLC10A1, GYS2, CPT1A | ALDH1A1 164/4885SYNJ2 2304/4885APP 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.